Bladder Cancer - Results from #820

REVIEW UroToday

Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial. October 3, 2023

Advantages of enhanced recovery after surgery program in robot-assisted radical cystectomy. October 2, 2023

Predictors of Response Following Neoadjuvant Cisplatin-Based Chemotherapy for Muscle Invasive Urothelial Bladder Cancer Using Molecular Profile: A Prospective Clinical Study. October 2, 2023

The Risk of Thromboembolism in Patients with Muscle Invasive Bladder Cancer before and after Cystectomy Depending on Blood Group and Neoadjuvant Chemotherapy-A Multicentre Retrospective Cohort Study. September 29, 2023

Molecular Markers for Bladder Cancer Screening: An Insight into Bladder Cancer and FDA-Approved Biomarkers. September 29, 2023

Microbial trends in infection-related readmissions following radical cystectomy for bladder cancer. September 28, 2023

Urinary comprehensive genomic profiling predicts urothelial carcinoma recurrence and identifies responders to intravesical therapy. September 28, 2023

Global Metanalysis of the Urinary Microbiome in Bladder Cancer Patients - Expert Commentary September 27, 2023

Adjuvant Hyperthermic Intravesical Chemotherapy in Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer. September 27, 2023

Health-related quality of life prior to and 1 year after radical cystectomy evaluated with FACT-G and FACT-VCI questionnaires. September 27, 2023

Enfortumab vedotin versus platinum rechallenge in post-platinum, post-pembrolizumab advanced urothelial carcinoma: A multicenter propensity score-matched study. September 26, 2023

Acute Kidney Injury within 90 days of Radical Cystectomy for Bladder Cancer: Incidence and Risk Factors. September 26, 2023

International Society of Urological Pathology (ISUP) Consensus Conference on Current Issues in Bladder Cancer: Working Group 3: Subcategorization of T1 Bladder Cancer. September 25, 2023

Systematic Evaluation of Imaging Features of Early Bladder Cancer Using Computed Tomography Performed before Pathologic Diagnosis. September 25, 2023

PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 Trial September 22, 2023

The Efficacy of Sequential Gemcitabine and Docetaxel in Intermediate-Risk Non Muscle Invasive Bladder Cancer - Expert Commentary September 22, 2023

Prognosis of patients with T1 low-grade urothelial bladder cancer treated with bacillus Calmette-Guérin immunotherapy. September 22, 2023

Clinical and dosimetric outcomes of image-guided, dose-painted radiotherapy in muscle invasive bladder cancer. September 22, 2023

Comparison of Robotic vs Open Cystectomy: A Systematic Review September 21, 2023

Prospective evaluation of return to work, health-related quality of life and psychosocial distress after radical cystectomy: 1-year follow-up in 230 employed German bladder cancer patients. September 21, 2023

Page 42 of 517